# Introduction:
Department

Here are preliminary results of the bibliometric mapping of the 2022 Luxembourg research evaluation. Its purpose is:

The method for the research-field-mapping can be reiviewed here:

Rakas, M., & Hain, D. S. (2019). The state of innovation system research: What happens beneath the surface?. Research Policy, 48(9), 103787.

Topic modelling

Topics by topwords

Topics over time

Knowledge Bases: Co-Citation network analysis

Note: This analysis refers the co-citation analysis, where the cited references and not the original publications are the unit of analysis. See tab Technical descriptionfor additional explanations

Knowledge Bases summary

Main Indicators

In order to partition networks into components or clusters, we deploy a community detection technique based on the Lovain Algorithm (Blondel et al., 2008). The Lovain Algorithm is a heuristic method that attempts to optimize the modularity of communities within a network by maximizing within- and minimizing between-community connectivity. We identify the following communities = knowledge bases.

com name dgr_int dgr
Knowledge Base 21: KB 1
1 COX J. MANN M. MAXQUANT ENABLES HIGH PEPTIDE IDENTIFICATION RATES INDIVIDUALIZED P.P.B.-RANGE MASS ACCURACIES AND PROTEOME-WIDE PROTEIN QUANTIFICAT… 9186 10106
1 COX J. NEUHAUSER N. MICHALSKI A. SCHELTEMA R.A. OLSEN J.V. MANN M. ANDROMEDA: A PEPTIDE SEARCH ENGINE INTEGRATED INTO THE MAXQUANT ENVIRONMENT (2011) 4417 4685
1 COX J. HEIN M.Y. LUBER C.A. PARON I. NAGARAJ N. MANN M. ACCURATE PROTEOME-WIDE LABEL-FREE QUANTIFICATION BY DELAYED NORMALIZATION AND MAXIMAL PEPTI… 3673 3940
1 TYANOVA S. TEMU T. SINITCYN P. CARLSON A. HEIN M.Y. GEIGER T. MANN M. COX J. THE PERSEUS COMPUTATIONAL PLATFORM FOR COMPREHENSIVE ANALYSIS OF (PROTE) 3152 3449
1 RAPPSILBER J. MANN M. ISHIHAMA Y. PROTOCOL FOR MICRO-PURIFICATION ENRICHMENT PRE-FRACTIONATION AND STORAGE OF PEPTIDES FOR PROTEOMICS USING STAGETI… 2937 3180
1 COX J. ANDROMEDA: A PEPTIDE SEARCH ENGINE INTEGRATED INTO THE MAXQUANT ENVIRONMENT (2011) 1270 1379
1 TYANOVA S. THE PERSEUS COMPUTATIONAL PLATFORM FOR COMPREHENSIVE ANALYSIS OF (PROTE) 1245 1469
1 COX J. ACCURATE PROTEOME-WIDE LABEL-FREE QUANTIFICATION BY DELAYED NORMALIZATION AND MAXIMAL PEPTIDE RATIO EXTRACTION TERMED MAXLFQ (2014) 990 1112
1 KULAK N.A. PICHLER G. PARON I. NAGARAJ N. MANN M. MINIMAL ENCAPSULATED PROTEOMIC-SAMPLE PROCESSING APPLIED TO COPY-NUMBER ESTIMATION IN EUKARYOTIC … 681 704
1 TYANOVA S. TEMU T. COX J. THE MAXQUANT COMPUTATIONAL PLATFORM FOR MASS SPECTROMETRY-BASED SHOTGUN PROTEOMICS (2016) 649 689
Knowledge Base 22: KB 2
2 BRENNAN C.W. THE SOMATIC GENOMIC LANDSCAPE OF GLIOBLASTOMA (2013) 1838 2007
2 LOVE M.I. HUBER W. ANDERS S. MODERATED ESTIMATION OF FOLD CHANGE AND DISPERSION FOR RNA-SEQ DATA WITH DESEQ2 (2014) 1557 2607
2 PATEL A.P. SINGLE-CELL RNA-SEQ HIGHLIGHTS INTRATUMORAL HETEROGENEITY IN PRIMARY GLIOBLASTOMA (2014) 1360 1479
2 VERHAAK R.G. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVANT SUBTYPES OF GLIOBLASTOMA CHARACTERIZED BY ABNORMALITIES IN PDGFRA IDH1 EGFR… 1295 1455
2 CECCARELLI M. MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS OF PROGRESSION IN DIFFUSE GLIOMA (2016) 1241 1319
2 SUBRAMANIAN A. GENE SET ENRICHMENT ANALYSIS: A KNOWLEDGE-BASED APPROACH FOR INTERPRETING GENOME-WIDE EXPRESSION PROFILES (2005) 1163 1411
2 DOBIN A. STAR: ULTRAFAST UNIVERSAL RNA-SEQ ALIGNER (2013) 1136 1257
2 BUTLER A. HOFFMAN P. SMIBERT P. PAPALEXI E. SATIJA R. INTEGRATING SINGLE-CELL TRANSCRIPTOMIC DATA ACROSS DIFFERENT CONDITIONS TECHNOLOGIES AND SPEC… 1083 1285
2 LI H. DURBIN R. FAST AND ACCURATE SHORT READ ALIGNMENT WITH BURROWS-WHEELER TRANSFORM (2009) 1020 1353
2 LI H. THE SEQUENCE ALIGNMENT/MAP FORMAT AND SAMTOOLS (2009) 946 985
Knowledge Base 23: KB 3
3 LOUIS D.N. PERRY A. REIFENBERGER G. VON DEIMLING A. FIGARELLA-BRANGER D. CAVENEE W.K. THE 2016 WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS O… 2265 2513
3 YAN H. PARSONS D.W. JIN G. MCLENDON R. RASHEED B.A. YUAN W. IDH1 AND IDH2 MUTATIONS IN GLIOMAS (2009) 2190 2380
3 VERHAAK R.G. HOADLEY K.A. PURDOM E. WANG V. QI Y. WILKERSON M.D. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVANT SUBTYPES OF GLIOBLASTOM… 2037 2231
3 STUPP R. MASON W.P. VAN DEN BENT M.J. WELLER M. FISHER B. TAPHOORN M.J. RADIOTHERAPY PLUS CONCOMITANT AND ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA (2… 2001 2143
3 COMPREHENSIVE GENOMIC CHARACTERIZATION DEFINES HUMAN GLIOBLASTOMA GENES AND CORE PATHWAYS (2008) 1722 4734
3 BRENNAN C.W. VERHAAK R.G. MCKENNA A. CAMPOS B. NOUSHMEHR H. SALAMA S.R. THE SOMATIC GENOMIC LANDSCAPE OF GLIOBLASTOMA (2013) 1575 1685
3 CECCARELLI M. BARTHEL F.P. MALTA T.M. SABEDOT T.S. SALAMA S.R. MURRAY B.A. MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS O… 1329 1488
3 PARSONS D.W. JONES S. ZHANG X. LIN J.C. LEARY R.J. ANGENENDT P. AN INTEGRATED GENOMIC ANALYSIS OF HUMAN GLIOBLASTOMA MULTIFORME (2008) 1251 1309
3 DANG L. WHITE D.W. GROSS S. BENNETT B.D. BITTINGER M.A. DRIGGERS E.M. CANCER-ASSOCIATED IDH1 MUTATIONS PRODUCE 2-HYDROXYGLUTARATE (2009) 1157 1214
3 ECKEL-PASSOW J.E. LACHANCE D.H. MOLINARO A.M. WALSH K.M. DECKER P.A. SICOTTE H. GLIOMA GROUPS BASED ON 1P/19Q IDH AND TERT PROMOTER MUTATIONS IN TU… 972 1031
Knowledge Base 24: KB 4
4 LOUIS D.N. PERRY A. REIFENBERGER G. VON DEIMLING A. FIGARELLA-BRANGER D. CAVENEE W.K. OHGAKI H. ELLISON D.W. THE 2016 WORLD HEALTH ORGANIZATION CLA… 2495 3091
4 VERHAAK R.G. HOADLEY K.A. PURDOM E. WANG V. QI Y. WILKERSON M.D. MILLER C.R. MESIROV J.P. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVAN… 1521 1754
4 YAN H. PARSONS D.W. JIN G. MCLENDON R. RASHEED B.A. YUAN W. KOS I. RIGGINS G.J. IDH1 AND IDH2 MUTATIONS IN GLIOMAS (2009) 1259 1418
4 BRENNAN C.W. VERHAAK R.G. MCKENNA A. CAMPOS B. NOUSHMEHR H. SALAMA S.R. ZHENG S. BERMAN S.H. THE SOMATIC GENOMIC LANDSCAPE OF GLIOBLASTOMA (2013) 1137 1406
4 PATEL A.P. TIROSH I. TROMBETTA J.J. SHALEK A.K. GILLESPIE S.M. WAKIMOTO H. CAHILL D.P. MARTUZA R.L. SINGLE-CELL RNA-SEQ HIGHLIGHTS INTRATUMORAL HET… 1015 1388
4 DANG L. WHITE D.W. GROSS S. BENNETT B.D. BITTINGER M.A. DRIGGERS E.M. FANTIN V.R. KEENAN M.C. CANCER-ASSOCIATED IDH1 MUTATIONS PRODUCE 2-HYDROXYGLU… 845 917
4 PARSONS D.W. JONES S. ZHANG X. LIN J.C. LEARY R.J. ANGENENDT P. MANKOO P. GALLIA G.L. AN INTEGRATED GENOMIC ANALYSIS OF HUMAN GLIOBLASTOMA MULTIFOR… 839 943
4 LOUIS D.N. OHGAKI H. WIESTLER O.D. CAVENEE W.K. BURGER P.C. JOUVET A. SCHEITHAUER B.W. KLEIHUES P. THE 2007 WHO CLASSIFICATION OF TUMOURS OF THE CE… 831 997
4 YAN H. PARSONS D.W. JIN G. MCLENDON R. RASHEED B.A. YUAN W. KOS I. BIGNER D.D. IDH1 AND IDH2 MUTATIONS IN GLIOMAS (2009) 821 937
4 STUPP R. MASON W.P. VAN DEN BENT M.J. WELLER M. FISHER B. TAPHOORN M.J. BELANGER K. BOGDAHN U. RADIOTHERAPY PLUS CONCOMITANT AND ADJUVANT TEMOZOLOM… 747 928
Knowledge Base 25: KB 5
5 WHITE E. DECONVOLUTING THE CONTEXT-DEPENDENT ROLE FOR AUTOPHAGY IN CANCER (2012) 2010 2026
5 LEVY J.M.M. TOWERS C.G. THORBURN A. TARGETING AUTOPHAGY IN CANCER (2017) 1844 1881
5 MATHEW R. KARANTZA-WADSWORTH V. WHITE E. ROLE OF AUTOPHAGY IN CANCER (2007) 1069 1075
5 WHITE E. THE ROLE FOR AUTOPHAGY IN CANCER (2015) 1015 1048
5 MIZUSHIMA N. YOSHIMORI T. LEVINE B. METHODS IN MAMMALIAN AUTOPHAGY RESEARCH (2010) 942 950
5 LEVINE B. KROEMER G. AUTOPHAGY IN THE PATHOGENESIS OF DISEASE (2008) 898 921
5 KIMMELMAN A.C. WHITE E. AUTOPHAGY AND TUMOR METABOLISM (2017) 751 769
5 MIZUSHIMA N. KOMATSU M. AUTOPHAGY: RENOVATION OF CELLS AND TISSUES (2011) 698 707
5 CHUDE C.I. AMARAVADI R.K. TARGETING AUTOPHAGY IN CANCER: UPDATE ON CLINICAL TRIALS AND NOVEL INHIBITORS (2017) 672 675
5 MIZUSHIMA N. LEVINE B. CUERVO A.M. KLIONSKY D.J. AUTOPHAGY FIGHTS DISEASE THROUGH CELLULAR SELF-DIGESTION (2008) 670 676
Knowledge Base 26: KB 6
6 VIVIER E. TOMASELLO E. BARATIN M. WALZER T. UGOLINI S. FUNCTIONS OF NATURAL KILLER CELLS (2008) 1855 1877
6 LONG E.O. KIM H.S. LIU D. PETERSON M.E. RAJAGOPALAN S. CONTROLLING NATURAL KILLER CELL RESPONSES: INTEGRATION OF SIGNALS FOR ACTIVATION AND INHIBIT… 1254 1260
6 GUILLEREY C. HUNTINGTON N.D. SMYTH M.J. TARGETING NATURAL KILLER CELLS IN CANCER IMMUNOTHERAPY (2016) 1243 1298
6 ALTER G. MALENFANT J.M. ALTFELD M. CD107A AS A FUNCTIONAL MARKER FOR THE IDENTIFICATION OF NATURAL KILLER CELL ACTIVITY (2004) 900 918
6 GONG J.H. MAKI G. KLINGEMANN H.G. CHARACTERIZATION OF A HUMAN CELL LINE (NK-92) 630 630
6 MILLER J.S. SOIGNIER Y. PANOSKALTSIS-MORTARI A. MCNEARNEY S.A. YUN G.H. FAUTSCH S.K. SUCCESSFUL ADOPTIVE TRANSFER AND IN VIVO EXPANSION OF HUMAN HA… 588 588
6 COOPER M.A. FEHNIGER T.A. CALIGIURI M.A. THE BIOLOGY OF HUMAN NATURAL KILLER-CELL SUBSETS (2001) 573 573
6 LANIER L.L. NK CELL RECOGNITION (2005) 546 550
6 VIVIER E. UGOLINI S. BLAISE D. CHABANNON C. BROSSAY L. TARGETING NATURAL KILLER CELLS AND NATURAL KILLER T CELLS IN CANCER (2012) 529 535
6 ORANGE J.S. FORMATION AND FUNCTION OF THE LYTIC NK-CELL IMMUNOLOGICAL SYNAPSE (2008) 529 529
Knowledge Base 27: KB 7
7 LOUIS D.N. PERRY A. REIFENBERGER G. THE 2016 WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS OF THE CENTRAL NERVOUS SYSTEM: A SUMMARY (2016) 3490 3711
7 YAN H. PARSONS D.W. JIN G. IDH1 AND IDH2 MUTATIONS IN GLIOMAS (2009) 3405 3621
7 PARSONS D.W. JONES S. ZHANG X. AN INTEGRATED GENOMIC ANALYSIS OF HUMAN GLIOBLASTOMA MULTIFORME (2008) 1996 2142
7 STUPP R. MASON W.P. VAN DEN BENT M.J. RADIOTHERAPY PLUS CONCOMITANT AND ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA (2005) 1906 2100
7 ECKEL-PASSOW J.E. LACHANCE D.H. MOLINARO A.M. GLIOMA GROUPS BASED ON 1P/19Q IDH AND TERT PROMOTER MUTATIONS IN TUMORS (2015) 1569 1658
7 DANG L. WHITE D.W. GROSS S. CANCER-ASSOCIATED IDH1 MUTATIONS PRODUCE 2-HYDROXYGLUTARATE (2009) 1501 1592
7 BRENNAN C.W. VERHAAK R.G. MCKENNA A. THE SOMATIC GENOMIC LANDSCAPE OF GLIOBLASTOMA (2013) 1387 1545
7 VERHAAK R.G. HOADLEY K.A. PURDOM E. INTEGRATED GENOMIC ANALYSIS IDENTIFIES CLINICALLY RELEVANT SUBTYPES OF GLIOBLASTOMA CHARACTERIZED BY ABNORMALIT… 1195 1347
7 CECCARELLI M. BARTHEL F.P. MALTA T.M. MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS OF PROGRESSION IN DIFFUSE GLIOMA (2016) 997 1085
7 HEGI M.E. DISERENS A.C. GORLIA T. MGMT GENE SILENCING AND BENEFIT FROM TEMOZOLOMIDE IN GLIOBLASTOMA (2005) 965 1014

Development of Knowledge Bases

Technical description

In a co-cittion network, the strength of the relationship between a reference pair \(m\) and \(n\) (\(s_{m,n}^{coc}\)) is expressed by the number of publications \(C\) which are jointly citing reference \(m\) and \(n\).

\[s_{m,n}^{coc} = \sum_i c_{i,m} c_{i,n}\]

The intuition here is that references which are frequently cited together are likely to share commonalities in theory, topic, methodology, or context. It can be interpreted as a measure of similarity as evaluated by other researchers that decide to jointly cite both references. Because the publication process is time-consuming, co-citation is a backward-looking measure, which is appropriate to map the relationship between core literature of a field.

Research Areas: Bibliographic coupling analysis

Research Areas main summary

This is arguably the more interesting part. Here, we identify the literature’s current knowledge frontier by carrying out a bibliographic coupling analysis of the publications in our corpus. This measure uses bibliographical information of publications to establish a similarity relationship between them. Again, method details to be found in the tab Technical description. As you will see, we identify the main research area, but also a set of adjacent research areas with some theoretical/methodological/application overlap.

Main Characteristics

To identify communities in the field’s knowledge frontier (labeled research areas) we again use the Lovain Algorithm (Blondel et al., 2008). We identify the following communities = research areas.

Categorization

I up to now gain only provide the 10 most central articles, which can be used to classify them

com_name AU PY TI dgr_int TC TC_year
Research Area 1: RA 1
RA 1 CECCARELLI M;BARTHEL F… 2016 MOLECULAR PROFILING REVEALS BIOLOGICALLY DISCRETE SUBSETS AND PATHWAYS OF PROGRESSION IN DIFFUSE GLIOMA 5.8280489 1083 180.500000
RA 1 WANG Q;HU B;HU X;KIM H… 2017 TUMOR EVOLUTION OF GLIOMA-INTRINSIC GENE EXPRESSION SUBTYPES ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT 6.2570923 632 126.400000
RA 1 LIU J;LICHTENBERG T;HO… 2018 AN INTEGRATED TCGA PAN-CANCER CLINICAL DATA RESOURCE TO DRIVE HIGH-QUALITY SURVIVAL OUTCOME ANALYTICS 3.0336201 974 243.500000
RA 1 COLAPRICO A;SILVA TC;O… 2016 TCGABIOLINKS: AN R/BIOCONDUCTOR PACKAGE FOR INTEGRATIVE ANALYSIS OF TCGA DATA 2.4672309 1070 178.333333
RA 1 NEFTEL C;LAFFY J;FILBI… 2019 AN INTEGRATIVE MODEL OF CELLULAR STATES, PLASTICITY, AND GENETICS FOR GLIOBLASTOMA 4.8991952 502 167.333333
RA 1 CHANDRASHEKAR DS;BASHE… 2017 UALCAN: A PORTAL FOR FACILITATING TUMOR SUBGROUP GENE EXPRESSION AND SURVIVAL ANALYSES 0.7837219 2159 431.800000
RA 1 SU R;DONG L;LI C;NACHT… 2018 R-2HG EXHIBITS ANTI-TUMOR ACTIVITY BY TARGETING FTO/M6A/MYC/CEBPA SIGNALING 2.6743798 479 119.750000
RA 1 CAVALLI FMG;REMKE M;RA… 2017 INTERTUMORAL HETEROGENEITY WITHIN MEDULLOBLASTOMA SUBGROUPS 2.0524417 508 101.600000
RA 1 LIAO Y;SMYTH GK;SHI W 2019 THE R PACKAGE RSUBREAD IS EASIER, FASTER, CHEAPER AND BETTER FOR ALIGNMENT AND QUANTIFICATION OF RNA SEQUENCING READS 1.8199566 539 179.666667
RA 1 JACOB F;SALINAS RD;ZHA… 2020 A PATIENT-DERIVED GLIOBLASTOMA ORGANOID MODEL AND BIOBANK RECAPITULATES INTER- AND INTRA-TUMORAL HETEROGENEITY 4.4926787 217 108.500000
Research Area 2: RA 2
RA 2 MAUTHE M;ORHON I;ROCCH… 2018 CHLOROQUINE INHIBITS AUTOPHAGIC FLUX BY DECREASING AUTOPHAGOSOME-LYSOSOME FUSION 0.8711046 744 186.000000
RA 2 SINGH SS;VATS S;CHIA A… 2018 DUAL ROLE OF AUTOPHAGY IN HALLMARKS OF CANCER 2.1865347 271 67.750000
RA 2 SHARIFI MN;MOWERS EE;D… 2016 AUTOPHAGY PROMOTES FOCAL ADHESION DISASSEMBLY AND CELL MOTILITY OF METASTATIC TUMOR CELLS THROUGH THE DIRECT INTERACTION O… 3.0563539 177 29.500000
RA 2 GUO JY;TENG X;LADDHA S… 2016 AUTOPHAGY PROVIDES METABOLIC SUBSTRATES TO MAINTAIN ENERGY CHARGE AND NUCLEOTIDE POOLS IN RAS-DRIVEN LUNG CANCER CELLS 2.5786047 206 34.333333
RA 2 PIETROCOLA F;POL J;VAC… 2016 CALORIC RESTRICTION MIMETICS ENHANCE ANTICANCER IMMUNOSURVEILLANCE 1.6069340 278 46.333333
RA 2 WHITE E 2016 AUTOPHAGY AND P53 2.6478072 168 28.000000
RA 2 YANG A;HERTER-SPRIE G;… 2018 AUTOPHAGY SUSTAINS PANCREATIC CANCER GROWTH THROUGH BOTH CELL-AUTONOMOUS AND NONAUTONOMOUS MECHANISMS 2.2279286 165 41.250000
RA 2 JANJI B;BERCHEM G;CHOU… 2018 TARGETING AUTOPHAGY IN THE TUMOR MICROENVIRONMENT: NEW CHALLENGES AND OPPORTUNITIES FOR REGULATING TUMOR IMMUNITY 6.8463433 45 11.250000
RA 2 HUANG T;KIM CK;ALVAREZ… 2017 MST4 PHOSPHORYLATION OF ATG4B REGULATES AUTOPHAGIC ACTIVITY, TUMORIGENICITY, AND RADIORESISTANCE IN GLIOBLASTOMA 2.6008058 117 23.400000
RA 2 KINSEY CG;CAMOLOTTO SA… 2019 PROTECTIVE AUTOPHAGY ELICITED BY RAF→MEK→ERK INHIBITION SUGGESTS A TREATMENT STRATEGY FOR RAS-DRIVEN CANCERS 1.0605398 269 89.666667
Research Area 3: RA 3
RA 3 GEIGER R;RIECKMANN JC;… 2016 L-ARGININE MODULATES T CELL METABOLISM AND ENHANCES SURVIVAL AND ANTI-TUMOR ACTIVITY 10.6605202 617 102.833333
RA 3 GEYER PE;KULAK NA;PICH… 2016 PLASMA PROTEOME PROFILING TO ASSESS HUMAN HEALTH AND DISEASE 16.7178052 330 55.000000
RA 3 MEIER F;BRUNNER A-D;KO… 2018 ONLINE PARALLEL ACCUMULATION–SERIAL FRAGMENTATION (PASEF) WITH A NOVEL TRAPPED ION MOBILITY MASS SPECTROMETER 14.6773418 243 60.750000
RA 3 WHITHAM M;PARKER BL;FR… 2018 EXTRACELLULAR VESICLES PROVIDE A MEANS FOR TISSUE CROSSTALK DURING EXERCISE 13.5161195 247 61.750000
RA 3 STEGER M;DIEZ F;DHEKNE… 2017 SYSTEMATIC PROTEOMIC ANALYSIS OF LRRK2-MEDIATED RAB GTPASE PHOSPHORYLATION ESTABLISHES A CONNECTION TO CILIOGENESIS 17.2448724 181 36.200000
RA 3 ITZHAK DN;TYANOVA S;CO… 2016 GLOBAL, QUANTITATIVE AND DYNAMIC MAPPING OF PROTEIN SUBCELLULAR LOCALIZATION 10.1717003 268 44.666667
RA 3 SCHROEDER BO;BIRCHENOU… 2018 BIFIDOBACTERIA OR FIBER PROTECTS AGAINST DIET-INDUCED MICROBIOTA-MEDIATED COLONIC MUCUS DETERIORATION 8.8777270 285 71.250000
RA 3 GRASSL N;KULAK NA;PICH… 2016 ULTRA-DEEP AND QUANTITATIVE SALIVA PROTEOME REVEALS DYNAMICS OF THE ORAL MICROBIOME 20.6468269 121 20.166667
RA 3 BONFIGLIO JJ;FONTANA P… 2017 SERINE ADP-RIBOSYLATION DEPENDS ON HPF1 14.7547585 157 31.400000
RA 3 BACHE N;GEYER PE;BEKKE… 2018 A NOVEL LC SYSTEM EMBEDS ANALYTES IN PRE-FORMED GRADIENTS FOR RAPID, ULTRA-ROBUST PROTEOMICS 21.2038243 107 26.750000
Research Area 4: RA 4
RA 4 TYANOVA S;TEMU T;COX J 2016 THE MAXQUANT COMPUTATIONAL PLATFORM FOR MASS SPECTROMETRY-BASED SHOTGUN PROTEOMICS 7.2284078 1476 246.000000
RA 4 FLAVAHAN WA;DRIER Y;LI… 2016 INSULATOR DYSFUNCTION AND ONCOGENE ACTIVATION IN IDH MUTANT GLIOMAS 4.6678120 684 114.000000
RA 4 WANG J;CAZZATO E;LADEW… 2016 CLONAL EVOLUTION OF GLIOBLASTOMA UNDER THERAPY 6.6121466 370 61.666667
RA 4 HOLDT LM;STAHRINGER A;… 2016 CIRCULAR NON-CODING RNA ANRIL MODULATES RIBOSOMAL RNA MATURATION AND ATHEROSCLEROSIS IN HUMANS 3.2621401 611 101.833333
RA 4 KLAEGER S;HEINZLMEIR S… 2017 THE TARGET LANDSCAPE OF CLINICAL KINASE DRUGS 5.2719097 365 73.000000
RA 4 LIAO M;LIU Y;YUAN J;WE… 2020 SINGLE-CELL LANDSCAPE OF BRONCHOALVEOLAR IMMUNE CELLS IN PATIENTS WITH COVID-19 1.7213505 978 489.000000
RA 4 NORTHCOTT PA;BUCHHALTE… 2017 THE WHOLE-GENOME LANDSCAPE OF MEDULLOBLASTOMA SUBTYPES 3.4096603 468 93.600000
RA 4 LAN X;JÖRG DJ;CAVALLI … 2017 FATE MAPPING OF HUMAN GLIOBLASTOMA REVEALS AN INVARIANT STEM CELL HIERARCHY 7.6028780 184 36.800000
RA 4 GHANDI M;HUANG FW;JANÉ… 2019 NEXT-GENERATION CHARACTERIZATION OF THE CANCER CELL LINE ENCYCLOPEDIA 1.4885165 871 290.333333
RA 4 BEN-DAVID U;SIRANOSIAN… 2018 GENETIC AND TRANSCRIPTIONAL EVOLUTION ALTERS CANCER CELL LINE DRUG RESPONSE 3.6065671 349 87.250000
Research Area 5: RA 5
RA 5 YEN K;TRAVINS J;WANG F… 2017 AG-221, A FIRST-IN-CLASS THERAPY TARGETING ACUTE MYELOID LEUKEMIA HARBORING ONCOGENIC IDH2 MUTATIONS 6.2735665 247 49.400000
RA 5 PATEL SH;POISSON LM;BR… 2017 T2–FLAIR MISMATCH, AN IMAGING BIOMARKER FOR IDH AND 1P/19Q STATUS IN LOWER-GRADE GLIOMAS: A TCGA/TCIA PROJECT 9.4231188 137 27.400000
RA 5 JIANG T;MAO Y;MA W;MAO… 2016 CGCG CLINICAL PRACTICE GUIDELINES FOR THE MANAGEMENT OF ADULT DIFFUSE GLIOMAS 3.6924784 263 43.833333
RA 5 JOHANNS TM;MILLER CA;D… 2016 IMMUNOGENOMICS OF HYPERMUTATED GLIOBLASTOMA: A PATIENT WITH GERMLINE POLE DEFICIENCY TREATED WITH CHECKPOINT BLOCKADE IMMU… 3.9996904 195 32.500000
RA 5 ZHANG C;CHENG W;REN X;… 2017 TUMOR PURITY AS AN UNDERLYING KEY FACTOR IN GLIOMA 4.6211040 162 32.400000
RA 5 CHANG K;BAI HX;ZHOU H;… 2018 RESIDUAL CONVOLUTIONAL NEURAL NETWORK FOR THE DETERMINATION OF IDH STATUS IN LOW- AND HIGH-GRADE GLIOMAS FROM MR IMAGING 4.1434875 174 43.500000
RA 5 QADDOUMI I;ORISME W;WE… 2016 GENETIC ALTERATIONS IN UNCOMMON LOW-GRADE NEUROEPITHELIAL TUMORS: BRAF, FGFR1, AND MYB MUTATIONS OCCUR AT HIGH FREQUENCY A… 3.4895022 205 34.166667
RA 5 CLARK O;YEN K;MELLINGH… 2016 MOLECULAR PATHWAYS: ISOCITRATE DEHYDROGENASE MUTATIONS IN CANCER 5.5145795 117 19.500000
RA 5 LU Y;KWINTKIEWICZ J;LI… 2017 CHEMOSENSITIVITY OF IDH1-MUTATED GLIOMAS DUE TO AN IMPAIRMENT IN PARP1-MEDIATED DNA REPAIR 4.4577173 112 22.400000
RA 5 TATEISHI K;HIGUCHI F;M… 2017 THE ALKYLATING CHEMOTHERAPEUTIC TEMOZOLOMIDE INDUCES METABOLIC STRESS IN IDH1-MUTANT CANCERS AND POTENTIATES NAD+ DEPLETIO… 8.2267674 55 11.000000
Research Area 6: RA 6
RA 6 STUPP R;TAILLIBERT S;K… 2017 EFFECT OF TUMOR-TREATING FIELDS PLUS MAINTENANCE TEMOZOLOMIDE VS MAINTENANCE TEMOZOLOMIDE ALONE ON SURVIVAL IN PATIENTS WI… 5.7216636 792 158.400000
RA 6 WELLER M;BUTOWSKI N;TR… 2017 RINDOPEPIMUT WITH TEMOZOLOMIDE FOR PATIENTS WITH NEWLY DIAGNOSED, EGFRVIII-EXPRESSING GLIOBLASTOMA (ACT IV): A RANDOMISED,… 4.5026974 468 93.600000
RA 6 CHOI C;RAISANEN JM;GAN… 2016 PROSPECTIVE LONGITUDINAL ANALYSIS OF 2-HYDROXYGLUTARATE MAGNETIC RESONANCE SPECTROSCOPY IDENTIFIES BROAD CLINICAL UTILITY … 16.9098945 109 18.166667
RA 6 BAUMERT BG;HEGI ME;VAN… 2016 TEMOZOLOMIDE CHEMOTHERAPY VERSUS RADIOTHERAPY IN HIGH-RISK LOW-GRADE GLIOMA (EORTC 22033-26033): A RANDOMISED, OPEN-LABEL,… 6.3553533 276 46.000000
RA 6 VAN DEN BENT MJ;BAUMER… 2017 INTERIM RESULTS FROM THE CATNON TRIAL (EORTC STUDY 26053-22054) OF TREATMENT WITH CONCURRENT AND ADJUVANT TEMOZOLOMIDE FOR… 8.6426310 198 39.600000
RA 6 SAHM F;SCHRIMPF D;STIC… 2017 DNA METHYLATION-BASED CLASSIFICATION AND GRADING SYSTEM FOR MENINGIOMA: A MULTICENTRE, RETROSPECTIVE ANALYSIS 4.9711527 335 67.000000
RA 6 DINARDO CD;STEIN EM;DE… 2018 DURABLE REMISSIONS WITH IVOSIDENIB IN IDH1-MUTATED RELAPSED OR REFRACTORY AML 2.4284092 677 169.250000
RA 6 HERRLINGER U;TZARIDIS … 2019 LOMUSTINE-TEMOZOLOMIDE COMBINATION THERAPY VERSUS STANDARD TEMOZOLOMIDE THERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLAST… 7.9386548 194 64.666667
RA 6 SHIRAHATA M;ONO T;STIC… 2018 NOVEL, IMPROVED GRADING SYSTEM(S) FOR IDH-MUTANT ASTROCYTIC GLIOMAS 8.9400711 162 40.500000
RA 6 CHANG P;GRINBAND J;WEI… 2018 DEEP-LEARNING CONVOLUTIONAL NEURAL NETWORKS ACCURATELY CLASSIFY GENETIC MUTATIONS IN GLIOMAS 6.8771745 178 44.500000
Research Area 7: RA 7
RA 7 LI Y;HERMANSON DL;MORI… 2018 HUMAN IPSC-DERIVED NATURAL KILLER CELLS ENGINEERED WITH CHIMERIC ANTIGEN RECEPTORS ENHANCE ANTI-TUMOR ACTIVITY 3.9649400 343 85.750000
RA 7 LIU E;MARIN D;BANERJEE… 2020 USE OF CAR-TRANSDUCED NATURAL KILLER CELLS IN CD19-POSITIVE LYMPHOID TUMORS 0.7612113 602 301.000000
RA 7 BÖTTCHER JP;BONAVITA E… 2018 NK CELLS STIMULATE RECRUITMENT OF CDC1 INTO THE TUMOR MICROENVIRONMENT PROMOTING CANCER IMMUNE CONTROL 0.6713876 630 157.500000
RA 7 HE C;DUAN X;GUO N;CHAN… 2016 CORE-SHELL NANOSCALE COORDINATION POLYMERS COMBINE CHEMOTHERAPY AND PHOTODYNAMIC THERAPY TO POTENTIATE CHECKPOINT BLOCKADE… 0.8359804 471 78.500000
RA 7 ABSI AA;WURZER H;GUERI… 2018 ACTIN CYTOSKELETON REMODELING DRIVES BREAST CANCER CELL ESCAPE FROM NATURAL KILLER-MEDIATED CYTOTOXICITY 6.4497796 59 14.750000
RA 7 SUCK G;ODENDAHL M;NOWA… 2016 NK-92: AN ‘OFF-THE-SHELF THERAPEUTIC’ FOR ADOPTIVE NATURAL KILLER CELL-BASED CANCER IMMUNOTHERAPY 2.2091283 167 27.833333
RA 7 ROMEE R;COOLEY S;BERRI… 2018 FIRST-IN-HUMAN PHASE 1 CLINICAL STUDY OF THE IL-15 SUPERAGONIST COMPLEX ALT-803 TO TREAT RELAPSE AFTER TRANSPLANTATION 1.9338437 190 47.500000
RA 7 BERCHEM G;NOMAN MZ;BOS… 2016 HYPOXIC TUMOR-DERIVED MICROVESICLES NEGATIVELY REGULATE NK CELL FUNCTION BY A MECHANISM INVOLVING TGF-Β AND MIR23A TRANSFER 1.8905019 188 31.333333
RA 7 ZHANG C;OBEROI P;OELSN… 2017 CHIMERIC ANTIGEN RECEPTOR-ENGINEERED NK-92 CELLS: AN OFF-THE-SHELF CELLULAR THERAPEUTIC FOR TARGETED ELIMINATION OF CANCER… 2.0802471 162 32.400000
RA 7 PFIRSCHKE C;ENGBLOM C;… 2016 IMMUNOGENIC CHEMOTHERAPY SENSITIZES TUMORS TO CHECKPOINT BLOCKADE THERAPY 0.5961364 519 86.500000
Research Area 8: RA 8
RA 8 CAPPER D;JONES DTW;SIL… 2018 DNA METHYLATION-BASED CLASSIFICATION OF CENTRAL NERVOUS SYSTEM TUMOURS 8.8334587 976 244.000000
RA 8 BIAU G;SCORNET E 2016 A RANDOM FOREST GUIDED TOUR 4.9630065 656 109.333333
RA 8 BERTSIMAS D;DUNN J 2017 OPTIMAL CLASSIFICATION TREES 5.8316420 195 39.000000
RA 8 GENUER R;POGGI J-M;TUL… 2017 RANDOM FORESTS FOR BIG DATA 5.2519781 161 32.200000
RA 8 PROBST P;BOULESTEIX A-L 2018 TO TUNE OR NOT TO TUNE THE NUMBER OF TREES IN RANDOM FOREST 10.3365076 81 20.250000
RA 8 KESSLER RC;HWANG I;HOF… 2017 DEVELOPING A PRACTICAL SUICIDE RISK PREDICTION MODEL FOR TARGETING HIGH-RISK PATIENTS IN THE VETERANS HEALTH ADMINISTRATION 9.3124037 89 17.800000
RA 8 VAN SMEDEN M;MOONS KGM… 2019 SAMPLE SIZE FOR BINARY LOGISTIC PREDICTION MODELS: BEYOND EVENTS PER VARIABLE CRITERIA 4.5360738 138 46.000000
RA 8 MEYER H;REUDENBACH C;H… 2018 IMPROVING PERFORMANCE OF SPATIO-TEMPORAL MACHINE LEARNING MODELS USING FORWARD FEATURE SELECTION AND TARGET-ORIENTED VALID… 5.6126935 110 27.500000
RA 8 SCORNET E 2016 RANDOM FORESTS AND KERNEL METHODS 7.1447199 78 13.000000
RA 8 CHEN Q;ZHANG M;XUE B 2017 FEATURE SELECTION TO IMPROVE GENERALIZATION OF GENETIC PROGRAMMING FOR HIGH-DIMENSIONAL SYMBOLIC REGRESSION 7.0550790 71 14.200000
Research Area 9: RA 9
RA 9 OSTROM QT;PATIL N;CIOF… 2020 CBTRUS STATISTICAL REPORT: PRIMARY BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMORS DIAGNOSED IN THE UNITED STATES IN 2013-2017 1.1713424 325 162.500000
RA 9 LOUIS DN;PERRY A;WESSE… 2021 THE 2021 WHO CLASSIFICATION OF TUMORS OF THE CENTRAL NERVOUS SYSTEM: A SUMMARY 0.3352943 560 560.000000
RA 9 OSTROM QT;CIOFFI G;WAI… 2021 CBTRUS STATISTICAL REPORT: PRIMARY BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMORS DIAGNOSED IN THE UNITED STATES IN 2014-2018 1.0231346 139 139.000000
RA 9 MELLINGHOFF IK;ELLINGS… 2020 IVOSIDENIB IN ISOCITRATE DEHYDROGENASE 1-MUTATED ADVANCED GLIOMA 1.4639475 62 31.000000
RA 9 BANGALORE YOGANANDA CG… 2020 A NOVEL FULLY AUTOMATED MRI-BASED DEEP-LEARNING METHOD FOR CLASSIFICATION OF IDH MUTATION STATUS IN BRAIN GLIOMAS 1.4181367 51 25.500000
RA 9 BELL EH;ZHANG P;SHAW E… 2020 COMPREHENSIVE GENOMIC ANALYSIS IN NRG ONCOLOGY/RTOG 9802: A PHASE III TRIAL OF RADIATION VERSUS RADIATION PLUS PROCARBAZIN… 1.5066524 42 21.000000
RA 9 BALANA C;VAZ MA;SEPÚLV… 2020 A PHASE II RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL OF CONTINUING ADJUVANT TEMOZOLOMIDE BEYOND 6 CYCLES IN PATIENTS WITH … 1.5650031 29 14.500000
RA 9 CHOI YS;BAE S;CHANG JH… 2021 FULLY AUTOMATED HYBRID APPROACH TO PREDICT THE IDH MUTATION STATUS OF GLIOMAS VIA DEEP LEARNING AND RADIOMICS 1.7269442 23 23.000000
RA 9 MATHUR R;ZHANG Y;GRIMM… 2020 MGMT PROMOTER METHYLATION LEVEL IN NEWLY DIAGNOSED LOW-GRADE GLIOMA IS A PREDICTOR OF HYPERMUTATION AT RECURRENCE 1.5395801 25 12.500000
RA 9 DEJAEGHER J;SOLIE L;HU… 2021 DNA METHYLATION BASED GLIOBLASTOMA SUBCLASSIFICATION IS RELATED TO TUMORAL T-CELL INFILTRATION AND PATIENT SURVIVAL 2.9815773 12 12.000000
Research Area 10: RA 10
NA BOURMAUD A;GALLIEN S;D… 2016 PARALLEL REACTION MONITORING USING QUADRUPOLE-ORBITRAP MASS SPECTROMETER: PRINCIPLE AND APPLICATIONS 0.2478120 162 27.000000
NA MARTINEZ-GARCIA E;LESU… 2016 DEVELOPMENT OF A SEQUENTIAL WORKFLOW BASED ON LC-PRM FOR THE VERIFICATION OF ENDOMETRIAL CANCER PROTEIN BIOMARKERS IN UTER… 0.2305195 20 3.333333
NA MARTINEZ-GARCIA E;LESU… 2017 TARGETED PROTEOMICS IDENTIFIES PROTEOMIC SIGNATURES IN LIQUID BIOPSIES OF THE ENDOMETRIUM TO DIAGNOSE ENDOMETRIAL CANCER A… 0.1369740 29 5.800000
NA KHRISTENKO NA;LARINA I… 2016 LONGITUDINAL URINARY PROTEIN VARIABILITY IN PARTICIPANTS OF THE SPACE FLIGHT SIMULATION PROGRAM 0.1360372 21 3.500000
NA DURIEZ E;MASSELON CD;M… 2017 LARGE-SCALE SRM SCREEN OF UROTHELIAL BLADDER CANCER CANDIDATE BIOMARKERS IN URINE 0.1334702 16 3.200000
NA MESMIN C;VAN OOSTRUM J… 2016 COMPLEXITY REDUCTION OF CLINICAL SAMPLES FOR ROUTINE MASS SPECTROMETRIC ANALYSIS 0.2458096 8 1.333333
NA TREVISIOL S;AYOUB D;LE… 2016 THE USE OF PROTEASES COMPLEMENTARY TO TRYPSIN TO PROBE ISOFORMS AND MODIFICATIONS 0.1088405 18 3.000000
NA MARTINEZ-GARCIA E;LOPE… 2018 ADVANCES IN ENDOMETRIAL CANCER PROTEIN BIOMARKERS FOR USE IN THE CLINIC 0.1259415 13 3.250000
NA LESUR A;GALLIEN S;DOMON B 2016 HYPHENATION OF FAST LIQUID CHROMATOGRAPHY WITH HIGH-RESOLUTION MASS SPECTROMETRY FOR QUANTITATIVE PROTEOMICS ANALYSES 0.0720779 11 1.833333
NA GREBBIN BM;HAU A-C;GRO… 2016 PBX1 IS REQUIRED FOR ADULT SUBVENTRICULAR ZONE NEUROGENESIS 0.0275229 25 4.166667

Development

Connectivity between the research areas

Knowledge Bases, Research Areas & Topics

Technical description

In a bibliographic coupling network, the coupling-strength between publications is determined by the number of commonly cited references they share, assuming a common pool of references to indicate similarity in context, methods, or theory. Formally, the strength of the relationship between a publication pair \(i\) and \(j\) (\(s_{i,j}^{bib}\)) is expressed by the number of commonly cited references.

\[s_{i,j}^{bib} = \sum_m c_{i,m} c_{j,m}\]

Since our corpus contains publications which differ strongly in terms of the number of cited references, we normalize the coupling strength by the Jaccard similarity coefficient. Here, we weight the intercept of two publications’ bibliography (shared refeences) by their union (number of all references cited by either \(i\) or \(j\)). It is bounded between zero and one, where one indicates the two publications to have an identical bibliography, and zero that they do not share any cited reference. Thereby, we prevent publications from having high coupling strength due to a large bibliography (e.g., literature surveys).

\[S_{i,j}^{jac-bib} =\frac{C(i \cap j)}{C(i \cup j)} = \frac{s_{i,j}^{bib}}{c_i + c_j - s_{i,j}^{bib}}\]

More recent articles have a higher pool of possible references to co-cite to, hence they are more likely to be coupled. Consequently, bibliographic coupling represents a forward looking measure, and the method of choice to identify the current knowledge frontier at the point of analysis.

Endnotes

All results are preliminary so far…